Jefferies Maintains Buy on Amarin

Jefferies is out with its report today on Amarin (NASDAQ: AMRN), maintaining Buy.

In a note to clients, Jefferies writes, "A competitor has raised questions raised over the validity of the statistical analyses used in the MARINE and ANCHOR studies, but for reasons we outline below, we remain positive on the statistical analysis plans and the eventual AMR101 commercial label. We continue to believe in a multi-billion market opportunity for AMR101. AMRN remains one of our top biotech picks."

Jefferies maintains a $25 PT on AMRN.

At the time of posting, shares of AMRN were trading pre-market at $18.86, up 1.84% from Thursday's close.